PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that data from its infectious disease portfolio will be presented at ID Week 2014, October 8-12 in Philadelphia, Pennsylvania.
“The Medicines Company continues to focus on developing solutions for infections caused by pathogens that Centers for Disease Control and others around the world consider to be serious threats to global health,” said Dr. Michael Dudley, Senior Vice President and Head of Health Science in the Infectious Disease Global Innovation Group. “We are excited to present additional analyses of ORBACTIV™ (oritavancin) for injection, as well as new clinical and nonclinical data regarding the investigational intravenous antibiotic, CARBAVANCE (meropenem/RPX7009), underscoring the Company’s commitment to supporting research and development of potential treatments for infections that pose a significant risk to society and healthcare systems globally.”
Help employers find you! Check out all the jobs and post your resume.
